{
  "extraction_metadata": {
    "timestamp": "2025-10-01T15:29:58.498691",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 40,
    "temperature": 0.3
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "patients with Child-Pugh stage A and BC or CLC HCC, distant metastases, or tumour metastasis that cannot be locally controlled or resected",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatic function (Child-Pugh Stage A), with distant metastases and/ or a tumour localization that cannot be locally controlled or resected",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "combination with the anti-perspirant therapy against PDLA1 and VEGF1",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5086
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "PICOs": [
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "arterial chemoembolization",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "radioactive Iodine 131 treatment",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tamoxifen",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic chemotherapy",
          "Outcomes": ""
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "octreotide",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5155
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "patients with Child-Pugh stage A and BC or CLC HCC, distant metastases, or tumour metastasis that cannot be locally controlled or resected",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with hepatic function (Child-Pugh Stage A), with distant metastases and/ or a tumour localization that cannot be locally controlled or resected",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "combination with the anti-perspirant therapy against PDLA1 and VEGF1",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5086
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with preserved hepatic function and in good general condition where resection, transplantation, ablation or TACE/ SIRT cannot be performed or are not expected to have an effect, or for patients with additional hepatic disease",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients in good performance with good liver function",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "transarterial chemoembolization (TACE)",
          "Outcomes": ""
        },
        {
          "Population": "patients in good performance with good liver function",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy",
          "Outcomes": ""
        },
        {
          "Population": "patients in good performance with good liver function",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tyrosine kinase inhibitors sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients in good performance with good liver function",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tyrosine kinase inhibitors regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients in good performance with good liver function",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tyrosine kinase inhibitors lenvatinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 4973
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "patients with advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "BSC",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 4127
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "PICOs": [],
      "ChunksUsed": 14,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma who progressed on sorafenib treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma and increased alpha-fetoprotein concentrations following first-line sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "best supportive care",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5572
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "patients with advanced and/ or unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "FOLVOX4",
          "Outcomes": ""
        },
        {
          "Population": "patients with advanced and/ or unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "doxorubicine",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 5159
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with (not locally treatable) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab with bevacizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients with (not locally treatable) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "patients with (not locally treatable) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": ""
        },
        {
          "Population": "patients with (not locally treatable) HCC who have progressed after first-line therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 4278
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients with non-surgical hepatocellular carcinoma in good general condition and with good liver function (Child and Pugha Class A)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "combination of bevacizumab and atezolizumab",
          "Outcomes": ""
        },
        {
          "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucyrumab",
          "Outcomes": ""
        },
        {
          "Population": "patients who are well tolerant of sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": ""
        },
        {
          "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": ""
        },
        {
          "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "leninivat",
          "Outcomes": ""
        },
        {
          "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 17,
      "ContextTokens": 2605
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "advanced HCC, such as metastasis or malignancy, taking into account overall cardiac function, liver disease and co-morbidity",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic oncological therapy",
          "Outcomes": ""
        }
      ],
      "ChunksUsed": 25,
      "ContextTokens": 4314
    }
  }
}